ATE310002T1 - Imidazotriazin-derivate als gaba-rezeptor- liganden - Google Patents
Imidazotriazin-derivate als gaba-rezeptor- ligandenInfo
- Publication number
- ATE310002T1 ATE310002T1 AT02747567T AT02747567T ATE310002T1 AT E310002 T1 ATE310002 T1 AT E310002T1 AT 02747567 T AT02747567 T AT 02747567T AT 02747567 T AT02747567 T AT 02747567T AT E310002 T1 ATE310002 T1 AT E310002T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor ligands
- gaba receptor
- derivatives
- imidazotriazine
- imidazotriazine derivatives
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title abstract 2
- XZLIYCQRASOFQM-UHFFFAOYSA-N 5h-imidazo[4,5-d]triazine Chemical class N1=NC=C2NC=NC2=N1 XZLIYCQRASOFQM-UHFFFAOYSA-N 0.000 title 1
- 102000005915 GABA Receptors Human genes 0.000 title 1
- 108010005551 GABA Receptors Proteins 0.000 title 1
- -1 (cyano)(fluoro)phenyl moiety Chemical group 0.000 abstract 1
- SKQCVELLWZOJOG-UHFFFAOYSA-N 7-phenylimidazo[1,2-b][1,2,4]triazine Chemical class C=1N=C2N=CC=NN2C=1C1=CC=CC=C1 SKQCVELLWZOJOG-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 102000027484 GABAA receptors Human genes 0.000 abstract 1
- 108091008681 GABAA receptors Proteins 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000036461 convulsion Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0117277.4A GB0117277D0 (en) | 2001-07-16 | 2001-07-16 | Therapeutic agents |
| PCT/GB2002/003114 WO2003008418A1 (en) | 2001-07-16 | 2002-07-08 | Imidazo-triazine derivatives as ligands for gaba receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE310002T1 true ATE310002T1 (de) | 2005-12-15 |
Family
ID=9918561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02747567T ATE310002T1 (de) | 2001-07-16 | 2002-07-08 | Imidazotriazin-derivate als gaba-rezeptor- liganden |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6617326B2 (de) |
| EP (1) | EP1409488B1 (de) |
| JP (1) | JP4373780B2 (de) |
| AT (1) | ATE310002T1 (de) |
| AU (1) | AU2002317957B2 (de) |
| CA (1) | CA2451445A1 (de) |
| DE (1) | DE60207416T2 (de) |
| ES (1) | ES2249598T3 (de) |
| GB (1) | GB0117277D0 (de) |
| PE (1) | PE20030432A1 (de) |
| WO (1) | WO2003008418A1 (de) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE310740T1 (de) * | 2000-11-10 | 2005-12-15 | Merck Sharp & Dohme | Imidazotriazin-derivate als liganden für gaba- rezeptoren |
| GB0128499D0 (en) * | 2001-11-28 | 2002-01-23 | Merck Sharp & Dohme | Therapeutic agents |
| GB0210124D0 (en) * | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
| GB0210127D0 (en) | 2002-05-02 | 2002-06-12 | Merck Sharp & Dohme | Therapeutic agents |
| US20070032553A1 (en) * | 2003-09-10 | 2007-02-08 | Mckernan Ruth | Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome |
| JP2007528416A (ja) * | 2004-03-11 | 2007-10-11 | セラヴァンス， インコーポレーテッド | ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物 |
| WO2007025177A2 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258359A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
| EP2377530A3 (de) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation von Neurogenese durch PDE-Hemmung |
| EP1942879A1 (de) * | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba-rezeptor-vermittelte modulation von neurogenese |
| CA2643199A1 (en) * | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2021000A2 (de) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenese mittels angiotensin-modulation |
| US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| MX2008014320A (es) * | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
| BRPI0716604A2 (pt) | 2006-09-08 | 2013-04-09 | Braincells Inc | combinaÇÕes contendo um derivado de 4-acilaminopiridina |
| AU2007299920A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| UA112028C2 (uk) | 2012-12-14 | 2016-07-11 | Пфайзер Лімітед | Похідні імідазопіридазину як модулятори гамка-рецептора |
| CA2951497C (en) | 2014-06-12 | 2019-04-09 | Pfizer Limited | Imidazopyridazine derivatives as modulators of the gabaa receptor activity |
| US10079661B2 (en) | 2015-09-16 | 2018-09-18 | At&T Intellectual Property I, L.P. | Method and apparatus for use with a radio distributed antenna system having a clock reference |
| JP7115746B2 (ja) | 2016-01-27 | 2022-08-09 | ウニヴェルズィテート・ツューリヒ | 掻痒の処置のためのｇａｂａａ受容体モジュレーターの使用 |
| CN112384513A (zh) * | 2018-04-18 | 2021-02-19 | 纽罗塞克医疗公司 | Gabaa正变构调节剂化合物、其制备方法和用途 |
| BR112021018528A2 (pt) * | 2019-03-18 | 2022-02-08 | Neurocycle Therapeutics Inc | Uso de moduladores do receptor gabaa para tratamento de dor |
| IL292340A (en) * | 2019-10-22 | 2022-06-01 | Neurocycle Therapeutics Inc | Gabaa positive allosteric modulator compounds, methods of preparation and uses thereof |
| BR112022007648A2 (pt) * | 2019-10-23 | 2022-10-11 | Neurocycle Therapeutics Inc | Tratamento de condições epilépticas com moduladores do receptor gabaa |
| CN120865250A (zh) | 2022-02-25 | 2025-10-31 | 上海赛默罗生物科技有限公司 | 咪唑并哒嗪类衍生物、其制备方法、药物组合物和用途 |
| CN117069725A (zh) | 2022-05-10 | 2023-11-17 | 上海赛默罗生物科技有限公司 | 咪唑并哒嗪取代苯环类衍生物、制备方法、药物组合物及用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3422194A (en) * | 1967-08-15 | 1969-01-14 | Smithkline Corp | The treatment of depression with imidazo(1,2-b)-as-triazines and compositions thereof |
| GB9702524D0 (en) | 1997-02-07 | 1997-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| BR0011823A (pt) * | 1999-06-22 | 2002-03-19 | Neurosearch As | Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo |
| GB9921150D0 (en) | 1999-09-07 | 1999-11-10 | Merck Sharp & Dohme | Therapeutic agents |
| GB9927687D0 (en) | 1999-11-23 | 2000-01-19 | Merck Sharp & Dohme | Therapeutic agents |
| JP2004501109A (ja) | 2000-05-24 | 2004-01-15 | メルク シャープ エンド ドーム リミテッド | Ｇａｂａ受容体に対するリガンドとしての３−フェニル−イミダゾ−ピリミジン誘導体 |
| GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
| GB0027561D0 (en) | 2000-11-10 | 2000-12-27 | Merck Sharp & Dohme | Therapeutic agents |
| ATE310740T1 (de) | 2000-11-10 | 2005-12-15 | Merck Sharp & Dohme | Imidazotriazin-derivate als liganden für gaba- rezeptoren |
| TWI248936B (en) | 2001-03-21 | 2006-02-11 | Merck Sharp & Dohme | Imidazo-pyrimidine derivatives as ligands for GABA receptors |
-
2001
- 2001-07-16 GB GBGB0117277.4A patent/GB0117277D0/en not_active Ceased
-
2002
- 2002-07-08 JP JP2003513977A patent/JP4373780B2/ja not_active Expired - Fee Related
- 2002-07-08 CA CA002451445A patent/CA2451445A1/en not_active Abandoned
- 2002-07-08 DE DE60207416T patent/DE60207416T2/de not_active Expired - Fee Related
- 2002-07-08 AT AT02747567T patent/ATE310002T1/de not_active IP Right Cessation
- 2002-07-08 AU AU2002317957A patent/AU2002317957B2/en not_active Ceased
- 2002-07-08 WO PCT/GB2002/003114 patent/WO2003008418A1/en not_active Ceased
- 2002-07-08 EP EP02747567A patent/EP1409488B1/de not_active Expired - Lifetime
- 2002-07-08 ES ES02747567T patent/ES2249598T3/es not_active Expired - Lifetime
- 2002-07-10 PE PE2002000616A patent/PE20030432A1/es not_active Application Discontinuation
- 2002-07-15 US US10/195,274 patent/US6617326B2/en not_active Expired - Fee Related
-
2003
- 2003-06-17 US US10/463,025 patent/US6696444B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20030216395A1 (en) | 2003-11-20 |
| ES2249598T3 (es) | 2006-04-01 |
| CA2451445A1 (en) | 2003-01-30 |
| DE60207416T2 (de) | 2006-08-03 |
| EP1409488B1 (de) | 2005-11-16 |
| GB0117277D0 (en) | 2001-09-05 |
| US6617326B2 (en) | 2003-09-09 |
| US20030055060A1 (en) | 2003-03-20 |
| EP1409488A1 (de) | 2004-04-21 |
| US6696444B2 (en) | 2004-02-24 |
| PE20030432A1 (es) | 2003-05-17 |
| JP4373780B2 (ja) | 2009-11-25 |
| WO2003008418A1 (en) | 2003-01-30 |
| DE60207416D1 (de) | 2005-12-22 |
| AU2002317957B2 (en) | 2007-10-25 |
| JP2004536862A (ja) | 2004-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60207416D1 (de) | Imidazotriazin-derivate als gaba-rezeptor-liganden | |
| ATE310740T1 (de) | Imidazotriazin-derivate als liganden für gaba- rezeptoren | |
| DE60012044D1 (de) | Imidazopyridinderivate als liganden für gaba-rezeptoren | |
| ATE323089T1 (de) | Imidazopyridin derivate als liganden für gaba rezeptoren | |
| BG108166A (en) | Imidazo-pyrimidine derivatives as liigands for gaba receptors | |
| DE60214532D1 (de) | Imidazopyrimidin-derivate als liganden für gaba-rezeptoren | |
| ATE371659T1 (de) | Pyrazolotriazinderivate als gaba-rezeptorliganden | |
| ATE284403T1 (de) | Triazolopyridazinderivate als liganden für gaba- rezeptoren | |
| ATE253066T1 (de) | Imidazotriazinderivate als gaba rezeptor-liganden | |
| TR199900047T2 (xx) | Gaba resept�rleri ligandlar� olarak ikame triazolo-piridazin t�revleri | |
| ATE335741T1 (de) | 8-fluorimidazo(1,2-a)pyridin derivative als liganden für gaba rezeptoren | |
| DE60006835D1 (de) | Imidazopyridinderivate als gaba rezeptor liganden | |
| ATE250062T1 (de) | Triazolopiridazinederivate als gaba rezeptor- liganden | |
| EA200000783A1 (ru) | Производные триазолопиридазина в качестве лигандов для гамк рецепторов | |
| ATE420867T1 (de) | Phenylpyridazin derivative als liganden für gaba- rezeptoren | |
| TW200609218A (en) | Bicyclic compounds | |
| JO2312B1 (en) | Imidazo-pyrimidine derivatives as associative groups of JABA receptors | |
| AR035876A1 (es) | Compuestos derivados de imidazo-triazina como ligandos para receptores gaba, composiciones farmaceuticas y uso de los compuestos en la fabricacion de medicamentos | |
| PE44299A1 (es) | Derivados sustituidos de triazolo-piridacina como ligandos para receptores gaba | |
| DK1419167T3 (da) | 1-(2,5'-anhydro-lyxofuranosyl) thyminer til syntese af radiomarkerede fluor-3 doxynucleotider |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |